---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-001494"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:39:16.505564+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma FY2024 net loss $17.5M; cash $9.9M; pipeline advances

## Summary
- Net loss of $17.5M ($1.72 per share) for FY2024, vs. $18.0M ($1.87) in 2023; R&D expenses $12.5M.
- Cash and equivalents $9.9M as of Dec 31 2024, down from $26.4M a year earlier; working capital $9.2M.
- Plans to initiate norovirus human challenge study in U.S. in 2025 for oral pan-viral protease inhibitor CDI-988.
- Will continue Phase 2a influenza challenge study of CC-42344 after low infection rate precluded efficacy data.
- Expects topline results from CDI-988 high-dose cohort in Q2 2025.

## SEC filing metadata
- accession: 0001641172-25-001494
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000164117225001494/0001641172-25-001494-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000164117225001494/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-001494
- JSON: https://secwatch.observer/filing/0001641172-25-001494.json
- Plain text: https://secwatch.observer/filing/0001641172-25-001494.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.